Market Research Logo

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2018

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2018, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 3, 16 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I and Preclinical stages comprises 3, 1 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Influenza A Virus, H3N2 Subtype Infections - Overview
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
AbbVie Inc
Adimmune Corp
Aphios Corp
AstraZeneca Plc
AusBio Ltd
BiondVax Pharmaceuticals Ltd
Cadila Healthcare Ltd
Celltrion Inc
ContraFect Corp
Emergent BioSolutions Inc
FluGen Inc
Inovio Pharmaceuticals Inc
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Medicago Inc
NanoViricides Inc
Novavax Inc
OPKO Health Inc
Sanofi
Sanofi Pasteur SA
Sarepta Therapeutics Inc
Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
APP-0205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-5075S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-5080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-1201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cetylpyridinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma-Flu - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H3N2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H3N2v] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain H3N2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/ Yamagata + B/ Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-2009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-2271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-8877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-61610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Influenza Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pimodivir hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNSIA-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radavirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDEE FLU - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for RSV and Influenza A Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTH-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
Featured News & Press Releases
Feb 21, 2018: AstraZeneca announces renewed recommendation and availability of FLUMIST QUADRIVALENT vaccine in the US
Jan 04, 2018: Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
Jan 12, 2017: Study Published in Vaccine Journal Indicates BiondVax’s Universal Flu Vaccine Candidate May Cover Strains Which Don’t Yet Exist
Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
Sep 30, 2015: Four-Strain Influenza Vaccine Available this Flu Season in Public Health Programs
Jan 15, 2013: NanoViricides Update: FluCide Drug Candidates Significantly Superior to Tamiflu in Animal Studies Against H3N2 and H1N1 viruses - Company announces that cGMP Facility Project has Entered Detailed Design Phase
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AstraZeneca Plc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AusBio Ltd, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Cadila Healthcare Ltd, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by ContraFect Corp, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Emergent BioSolutions Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2018
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2018 (Contd..1), H2 2018
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report